Much of Daniel’s work involves representing domestic and multinational clients during criminal and civil investigations at both the federal and state levels, as well as assisting clients with their own internal inquiries.
Daniel is highly experienced on multijurisdictional investigations and matters involving compliance with the US Foreign Corrupt Practices Act and other anticorruption laws, international compliance risks, economic sanctions laws, and claims involving allegations of securities fraud, unfair trade practices, consumer fraud and product liability.
Daniel advises clients on developing compliance and training programs tailored to relevant global regulatory regimes, and conducting due diligence regarding bribery and other compliance risks in corporate transactions.
- Defending a multinational company in an investigation conducted by the US Department of Justice (DOJ) and Securities and Exchange Commission (SEC) into relationships with officials in countries in Asia, Latin America, Europe and Africa.
- Conducting an internal investigation and defending a company in an inquiry by a multilateral development bank into allegations of fraudulent and corrupt practices.
- Conducting global antibribery and corruption due diligence and compliance program reviews for clients around the world.
- Conducting pre-acquisition due diligence for a global pharmaceutical company and assessing corruption risks associated with a multibillion-dollar asset swap, including advising on key transaction terms, compliance representations and warranties and related indemnities.
- Representing multinational pharmaceutical and medical device companies in investigations conducted by the DOJ, the SEC and the state attorneys general regarding relationships with healthcare professionals, and the marketing, promotion and safety of various products.
- Advising pharmaceutical companies regarding claims made under the False Claims Act, involving allegations of off-label promotion of prescription medications, improper relationships with healthcare professionals, and failure to disclose clinical trial data.
